Remdesivir [1809249-37-3]
Cat# HY-104077-1mg
Size : 1mg
Brand : MedChemExpress
Remdesivir (GS-5734), un analogue nucléosidique avec une activité antivirale efficace, a des EC50s de 74 nM pour SARS-CoV et MERS-CoV dans les cellules AOH et 30 nM pour le virus de l'hépatite murine dans les cellules tumorales cérébrales retardées. Remdesivir est très efficace dans le contrôle de l’infection par le SRAS-CoV-2 (COVID-19) in vitro.
Remdesivir (GS-5734), a nucleoside analogue with effective antiviral activity, has EC50s of 3.3 μM, 4.7 μM, 32 μM, 3.7 μM and 9.2 μM for SARS-CoV-2 and its variants alpha, beta, gamma and delta, respectively. Remdesivir is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro.
For research use only. We do not sell to patients.
Remdesivir Chemical Structure
CAS No. : 1809249-37-3
This product is a controlled substance and not for sale in your territory.
Based on 161 publication(s) in Google Scholar
Other Forms of Remdesivir:
- GS-441524 Get quote
- Remdesivir-d5 Get quote
- Remdesivir-d4 Get quote
- Remdesivir impurity 9-d4 Get quote
- GS-443902 Get quote
- Remdesivir-13C6 Get quote
- Remdesivir maleate Get quote
- Remdesivir (Standard) Get quote
Description |
Remdesivir (GS-5734), a nucleoside analogue with effective antiviral activity, has EC50s of 3.3 μM, 4.7 μM, 32 μM, 3.7 μM and 9.2 μM for SARS-CoV-2 and its variants alpha, beta, gamma and delta, respectively. Remdesivir is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro[1][2][3]. |
IC50 & Target |
EC50: 30 nM (murine hepatitis virus, delayed brain tumor cell), 74 nM (SARS-CoV, HAE cell), 74 nM (MERS-CoV, HAE cell)[1] |
||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
In Vitro |
Remdesivir (GS-5734) inhibits murine hepatitis virus (MHV) with an EC50 of 30 nM, and blocks SARS-CoV and MERS-CoV in HAE cells with EC50s of both 74 nM in HAE cells after treatment for 24 h[1]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||
Clinical Trial |
|
||||||||||||
Molecular Weight |
602.58 |
||||||||||||
Formula |
C27H35N6O8P |
||||||||||||
CAS No. |
1809249-37-3 |
||||||||||||
Appearance |
Solid |
||||||||||||
Color |
Off-white to yellow |
||||||||||||
SMILES |
C[C@H](N[P@@](OC1=CC=CC=C1)(OC[C@H]2O[C@@](C#N)(C3=CC=C4C(N)=NC=NN43)[C@H](O)[C@@H]2O)=O)C(OCC(CC)CC)=O |
||||||||||||
Shipping | Room temperature in continental US; may vary elsewhere. |
||||||||||||
Storage |
|
||||||||||||
Solvent & Solubility |
In Vitro:
DMSO : 100 mg/mL (165.95 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) Preparing
Stock Solutions
View the Complete Stock Solution Preparation Table
*
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol) Concentration (start) × Volume (start) = Concentration (final) × Volume (final) This equation is commonly abbreviated as: C1V1 = C2V2 In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
Dosage mg/kgAnimal weight Dosing volume Number of animals Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO
+
%
+
%
Tween-80
+
%
Saline
The co-solvents required include: DMSO,
. All of co-solvents are available by MedChemExpress (MCE).
, Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration:
mg/mL
Method for preparing stock solution:
mg
drug dissolved in
μL
DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take
μL DMSO stock solution, add
μL .
μL , mix evenly, next add
μL Tween 80, mix evenly, then add
μL Saline.
If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
|
||||||||||||
Purity & Documentation |
Purity: 99.95% |
||||||||||||
References |
|
Complete Stock Solution Preparation Table
*
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
---|
DMSO | 1 mM | 1.6595 mL | 8.2977 mL | 16.5953 mL | 41.4883 mL |
5 mM | 0.3319 mL | 1.6595 mL | 3.3191 mL | 8.2977 mL | |
10 mM | 0.1660 mL | 0.8298 mL | 1.6595 mL | 4.1488 mL | |
15 mM | 0.1106 mL | 0.5532 mL | 1.1064 mL | 2.7659 mL | |
20 mM | 0.0830 mL | 0.4149 mL | 0.8298 mL | 2.0744 mL | |
25 mM | 0.0664 mL | 0.3319 mL | 0.6638 mL | 1.6595 mL | |
30 mM | 0.0553 mL | 0.2766 mL | 0.5532 mL | 1.3829 mL | |
40 mM | 0.0415 mL | 0.2074 mL | 0.4149 mL | 1.0372 mL | |
50 mM | 0.0332 mL | 0.1660 mL | 0.3319 mL | 0.8298 mL | |
60 mM | 0.0277 mL | 0.1383 mL | 0.2766 mL | 0.6915 mL | |
80 mM | 0.0207 mL | 0.1037 mL | 0.2074 mL | 0.5186 mL | |
100 mM | 0.0166 mL | 0.0830 mL | 0.1660 mL | 0.4149 mL |
Remdesivir Related Classifications
- Cell Cycle/DNA Damage Anti-infection
- DNA/RNA Synthesis SARS-CoV